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ORIGINAL ARTICLE
Metabolic responses to long-term pharmacological
inhibition of CB1-receptor activity in mice in relation
to dietary fat composition
AH Koolman1, VW Bloks1, MH Oosterveer1, I Jonas2, F Kuipers1, PJJ Sauer1 and G van Dijk2,3
1Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
2Unit Neuroendocrinology, Center for Behavioral Neurosciences, University of Groningen, Haren, The Netherlands and
3Center for Isotope Research, University of Groningen, Groningen, The Netherlands
Background and objectives: The antiobesity effects of suppressed endocannabinoid signaling may rely, at least in part, on
changes in lipid fluxes. As fatty acids exert specific effects depending on their level of saturation, we hypothesized that the
dietary fatty acid composition would influence the outcome of treatment with a CB1-receptor antagonist (rimonabant).
Methods: Mice were treated with rimonabant (10mgkg1 body weight per day) or vehicle while equicalorically fed either a
low-fat diet (LF), a high-fat (HF) diet or an HF diet in which 10% of the saturated fatty acids (SFAs) were replaced by poly-
unsaturated fatty acids (PUFA) from fish oil (FO). Food intake and body weight were registered daily. Indirect calorimetry was
performed and feces were collected. After 3 weeks, mice were killed for blood and tissue collection.
Results: Relative to the LF diet, the HF diet caused anticipated metabolic derangements, which were partly reversed by the
HF/FO diet. The HF/FO diet, however, was most obesity-promoting despite inhibiting lipogenesis as indicated by low gene
expression levels of lipogenic enzymes. On all three diets, rimonabant treatment improved metabolic derangements and led to
significantly lower body weight gain than their respective controls. This latter effect appeared largest in the HF/FO group, but
occurred without major changes in nutrient absorption and energy expenditure.
Conclusion: The effects of chronic rimonabant treatment on body weight gain occurred irrespective of diet-induced changes in
lipogenic activity, food intake and daily energy expenditure, and were, in fact, most pronounced in HF/FO mice. The effects of
dietary PUFA replacement in an HF diet on expansion of adipose tissue might allow the favorable effects of dietary PUFA on
dyslipidemia and hepatic steatosis. In light of other disadvantageous effects of weight gain, this might be a risky trade-off.
International Journal of Obesity (2010) 34, 374–384; doi:10.1038/ijo.2009.219; published online 20 October 2009
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Introduction
Detailed understanding of the mechanisms involved in
regulation of energy balance is crucial for treatment and
prevention of obesity and associated comorbidities. The
endocannabinoid system (ECS) has recently been implicated
in the regulation of energy balance.1–3 The psychoactive
substance, D9-tetrahydrocannabinol, as well as endogenous
ligands of the ECS, anandamide and 2-arachidonoylglycerol,
stimulate food intake by activation of CB1-receptors.
4–7 CB1-
receptor-null mice are lean and resistant to diet-induced
obesity.8–11 Consistent with these findings, the CB1-receptor
antagonist SR141716, also known as rimonabant, was
shown to be able to reduce food intake and body weight in
obese humans.12,13 In humans as well as in rodents the
effects of CB1-receptor antagonism on food intake are
generally transient, whereas changes in body fat content
upon treatment are more persistent,7,14–16 suggesting a role
for the ECS in energy fluxes independent of food intake.
In line with this are several reports to indicate that CB1-
receptor activity affects lipid mobilization and utilization.
With respect to fat tissue, for example, Matias et al.17 observed
direct effects of endocannabinoids on lipid droplet formation
in mouse and human adipocytes, and these effects could be
prevented by CB1-receptor antagonism.
2 Furthermore, Cota
et al.10 found that stimulation of CB1-receptors of primary
adipocytes increases lipoprotein lipase activity, an effect that
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could be blocked by co-administration of the CB1-receptor
antagonist rimonabant. Jbilo et al.18 found that treatment with
this CB1-receptor antagonist increases gene expression of
enzymes involved in lipolysis and b-oxidation in white and
brown adipose tissue. Herling et al.19 and Osei-Hyiaman
et al.19,20 independently reinforced these results by showing
increased rates of lipid oxidation (by indirect calorimetry)
following bolus administration of rimonabant, particularly
during the post-ingestive phase. Finally, CB1-receptor antago-
nist in obese patients consistently improved plasma lipid
profiles.12,13,21 With respect to the liver, Osei-Hyiaman et al.11
observed that feeding a high-fat (HF) diet increases hepatic
levels of anandamide and CB1-receptor density, and showed
that pharmacological activation of CB1-receptors by HU210 in
mice increases hepatic gene expression of Srebp-1c (srebf1),Acc1
(Acaca) and Fasn, all indicative of increased lipogenesis. While
CB1-receptor-null mice have reduced hepatic lipogenesis,
20
which was suggested to explain their lean phenotype, data on
the effects of chronic rimonabant-treatment on markers of
hepatic lipogenesis are currently lacking. Taken together, these
data indicate that CB1-receptor antagonism is a useful tool
against disturbances in lipid fluxes known to be underlying, or
at least associated with, the ‘metabolic syndrome’.
It is generally accepted that not only the quantity of dietary
fat intake, but also its quality affects lipid fluxes in the body.22
Thus, while a high-saturated-fat diet stimulates the expression
of genes encoding lipogenic enzymes in the liver, such as
Srebp-1c and Fasn expression,23 a diet with a high content
of poly-unsaturated fatty acids (PUFAs) has the opposite
effects.24,25 Since changes in lipid fluxes are suggested to be,
at least in part, responsible for the antiobesity effect of rimona-
bant treatment, it can be hypothesized that efficacy of rimona-
bant treatment may depend on changes in lipid fluxes resulting
from differences in dietary fat composition. Up till now, relati-
vely little attention has been paid to the role of dietary fat
composition in relation to the efficacy of rimonabant treat-
ment. Humans consume food that varies considerably in fat
content and in the ratio of saturated fatty acids (SFAs) to PUFAs.
In fact, because of presumed favorable effects on lipid profiles
and on the risk for atherosclerosis, PUFA supplementation is
popular in those at risk of obesity-associated comorbidities.
As different fatty acids have specific effects on lipid fluxes
and compartmentalization of triglycerides in the body, we
hypothesized that differences in dietary fatty acid composi-
tion will influence the outcome of treatment with a CB1-
receptor antagonist like rimonabant. Therefore we performed
a controlled study of mice in which we analyzed the effects of
dietary fatty acid composition in relation to treatment with
rimonabant on obesity-associated derangements.
Materials and methods
Animals
Eight-week-old male C57BL/6J mice were obtained from
Harlan (Zeist, The Netherlands) and were individually
housed in a light-controlled (lights on 8 AM–8 PM) and
temperature-controlled (21 1C) facility. Mice were allowed
tap water and food ad libitum. Experimental protocols were
approved by the local Experimental Ethical Committee for
Animal Experiments. We certify that all applicable institu-
tional and governmental regulations concerning the ethical
use of animals were followed during this research.
Experimental diets
All experimental diets were obtained from Abdiets BV
(Woerden, The Netherlands). Mice received either a low-fat
(LF) diet (standard laboratory chow RMH-B 2103), an HF diet
containing 36 weight % fat consisting of bovine fat (custom
synthesis, diet number 4031.45) or a HF fish-oil-enriched
diet (HF/FO) containing 36 weight % fat consisting for 58%
of bovine fat and for 42% of fish oil (FO), (custom synthesis,
diet number 4031.54). After preparing pellets, diets were
stored at 20 1C. The HF/FO diet was replaced every 2 days to
prevent oxidation of fatty acid species. For diet composition,
see Table 1.
Experimental procedures
The effect of dietary PUFA and fat intake, the effect of
treatment with a CB1-receptor antagonist and the inter-
action between diet and this treatment were studied in a
Latin square design. On arrival, mice were divided into three
dietary groups: LF, HF and HF/FO. Mice were matched
for plasma lipids, glucose and body weight. Half of the
animals in each dietary group were subjected to CB1-receptor
antagonist (rimonabant) treatment. Thus, six groups of eight
mice were compared in this experiment.
Intake and body weight were registered daily. Rimonabant
(reference compound kindly provided by Solvay) was
administered orally at a dose of approximately 10mgkg1
body weight per day by thoroughly mixing it through the
diet. Oral rimonabant treatment was started after 3 weeks on
the various diets. Indirect 24-h calorimetry was performed
before start of treatment with the CB1 antagonist and
Table 1 Fatty acid profiles of experimental diets in mgg1
LF HF HF/FO
C14:0 0.5 12.2 16.1
C16:0 8.4 92.5 79.5
C16:1 0.7 11.5 18.0
C18:0 3.7 76.3 50.5
C18:1 13.7 133.2 101.0
C18:2 16.9 11.5 9.7
C18:3 1.9 2.9 15.2
C20–22 0.4 4.0 53.3
C16 desaturation index 0.1 0.1 0.2
C18 desaturation index 3.7 1.7 2.0
Ratio n-6/n-3 12.0 NDa 0.4
Total dietary fat content 6% 36% 36%
Abbreviations: FO, fish oil; HF, high fat; LF, low fat; ND, not detectable.
aThe level of n-6 PUFAs in the HF diet are ND. Composition of experimental
diets.
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2 weeks after start of treatment. Feces were collected before
start of treatment and after 18 days of treatment. After
3 weeks of oral rimonabant treatment (and thus 6 weeks after
the start of the diets), treated and control mice were killed,
blood and tissue were collected.
Indirect calorimetry
Mice were placed in an open-circuit, indirect calorimetry
system for 24h with access to water and food. Gas-exchange
measurements were performed with an eight-channel, open-
flow system. Flow rates were measured and controlled with a
mass flow controller. O2 and CO2 concentrations of dried
inlet and outlet air from each chamber were measured every
10min with a paramagnetic O2 analyzer and an infrared CO2
gas analyzer. Data were collected from each metabolic cage
separately. The respiratory quotient (RQ) was defined as CO2
production (l)/O2 consumption (l). Energy expenditure was
calculated according to Brouwer26 using the following
equation: (16.8*VO2*0.001)þ (5.02*VCO2*0.001). Lipid
oxidation and carbohydrate oxidation were calculated
according to Lusk using the following equations:27
Lipid oxidationðg=hrÞ : 38:461  ðVO2ðmol=hrÞ  VCO2ðmol=hrÞÞ
Carbohydrate oxidationðg=hrÞ : 94:017  VCO2ðmol=hrÞ  66:239  ðVO2ðmol=hrÞ
Feces
The energy content of dried, homogenized feces was
determined using a bomb calorimeter (CBB 330, standard
benzoic acid 6320 cal g1, BCS-CRM no.90N).
Plasma lipids and adipokines
Plasma lipids were measured using commercially available
kits from Roche (Mannheim, Germany) for triglycerides
and cholesterol. Plasma leptin, resistin and tumor necrosis
factor-a levels were determined using a commercially avail-
able adipokine lincoplex kit (Linco Research, St Charles,
MO, USA). Adiponectin was measured using a commercially
available RIA kit (Linco Research).
Hepatic lipids
Livers were removed and freeze-clamped. Before further
analysis, livers were crushed on liquid nitrogen and stored at
80 1C. For hepatic lipid extraction, frozen crushed livers
were homogenized in ice-cold saline. Hepatic lipids were
extracted according to Bligh and Dyer28 and hepatic
triglycerides and total cholesterol were measured using
commercially available kits from Roche; free cholesterol
was measured using a commercially available kit from Wako
Chemicals (Neuss, Germany). Phospholipid content of the
liver was determined according to Bo¨ttcher et al.29
Gene expression in liver and epididymal adipose tissue
Total RNA was isolated from frozen liver and epididymal adi-
pose tissue using the TRI-reagent method (Sigma, Zwijndrecht,
The Netherlands). Using random primers, RNA was converted
to cDNA with M-MuLV Reverse Transcriptase (Sigma) accord-
ing to the manufacturer’s protocol. For real-time PCR, cDNA
was amplified using the appropriate primers and probes.
The sequences of the primers and probes for b-actin,
Srebp-1c (Srebf1), Fasn, Acc1 (Acaca) and Acc2 (Acacb) have
been published (http://www.labpediatricsRUG.nl Realtime
Primers Datalist Pediatrics UMCG). Relative gene expression
levels were normalized to b-actin expression.
Body composition
Carcasses were eviscerated and stored at 20 1C. Carcasses
and organs were dried to constant weight at 103 1C, and fat
was extracted by using petroleum ether (Boom BV, Meppel,
The Netherlands) in a soxlet apparatus. Percentage fat of
carcasses and organs were determined from weight differ-
ences before and after the fat extraction procedure.
Statistical analysis
All values in the figures and in the tables represent means±
standard errors of the means for the number of animals
indicated in the figure and table legends. To evaluate effects
of diet, rimonabant treatment and their interactions, data
were statistically analyzed using a general linear model with
Bonferroni post hoc analyses. Treatment effects were further
analyzed by Student’s t-test. In case of non-parametric
distribution, Mann–Whitney U-test was used for statistical
analysis. Statistical significance of differences was accepted
at a P-value of less than 0.05. Analyses were performed using
SPSS 16.0 for Windows software (SPSS, Chicago, IL, USA).
Results
Effects of dietary fat composition on body weight gain, adiposity
and food efficiency in C57BL/6J mice
Mice were matched for serum levels of glucose, triglycerides
and total cholesterol, as well as for body weight at the onset
of the experiment. Figure 1a shows changes in body weight
relative to initial weights from the start of the experimental
diets. In the control groups on all the three experimental
diets, body weights increased over the course of the
experiment, but most pronounced in HF/FO-fed mice. At
day 22, body weights of mice fed HF/FO were significantly
increased compared with that of mice fed the LF and mice
fed the HF diet (Figure 1b). Data on body composition shown
in Table 2 illustrate that increased body weight in HF/FO-fed
mice was associated with increased adiposity in these mice as
compared with that in HF-fed mice and LF-fed mice. There
was a significant increase in fat mass in mice fed the HF/FO
diet as compared with that in mice fed LF as well as that in
mice fed the HF diet. Dietary fat composition did not affect
body fat distribution as is shown in Figure 1c.
Increased weight gain in the HF/FO group could not be
explained by higher food intake. In fact, mice fed the HF/FO
diet had slightly reduced caloric intake; however, this trend
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did not reach statistical significance (Figures 1d and e). To
assess whether increased absorption could contribute to
increased body weight gain in mice fed HF/FO, residual
energy contents in feces collected over a period of 48h were
determined using bomb calorimetry (Figure 2a). Fecal energy
excretion was significantly lower in the HF/FO control group
(1.58 kcal 24h1±0.45) as compared with that in the LF
control group (3.11 kcal/24h±0.47; P¼0.000) and the HF
control group (2.22 kcal 24h1±0.37; P¼0.037). Reduction
of fecal energy excretion in the HF control group as
compared with that in the LF control group was also
significant (P¼0.008). However, calculated as absorbed
energy (food intake in kcal 24h1 minus residual fecal
energy in kcal 24h1), the amount of absorbed energy was
not affected by diet as shown in Figure 2b.
Food efficiency (body weight gain in gram per kilocalorie
intake) calculated for the treatment period is shown in
Figure 2c. Food efficiency of mice in the HF/FO control
Figure 1 Body weight gain and food intake. (a) Body weight gain compared with body weight at the start of diet expressed in grams per day. On day 0, oral
treatment with rimonabant was started as indicated by the arrow. Open squares, LF C (LF control group); black squares, LF R (LF treatment group); open triangles,
HF C (HF control group); black triangles, HF R (HF treatment group); open circles, HF/FO C (HF/FO control group); black circles, HF/FO R (HF/FO treatment group).
Values are means for n¼ 8 mice per group. Body weight at day 0 (means±s.d. for n¼ 16 mice per diet group), LF group 25.6±1.4, HF group 28.3±2.0, HF/FO
group 27.0±2.2. (b). Body weight gain between days 0 and 22. Open bars, control groups; black bars, rimonabant treatment groups. Values are means±s.e.m. for
n¼8 mice per group. *, LF R versus LF C, P¼ 0.002; w, HF R versus HF C, P¼0.001; z, HF/FO R versus HF/FO C, P¼0.000. Trend towards significant interaction
between treatment and diet, P¼ 0.063. (c). Cumulative intake day 0 until day 22 expressed in kilocalories. Open bars, control groups; black bars, treatment groups.
Values are means±s.e.m. for n¼ 8 mice per group, *, HF R versus HF C, P¼ 0.020; w, HF/FO R versus HF/FO C, P¼0.000. Significant interaction between treatment
and diet, P¼ 0.003. (d). Cumulative intake day 11 until day 22 expressed in calories. Open bars, control groups; black bars, treatment groups. Values are
means±s.e.m. for n¼8 mice per group. No significant differences. FO, fish oil; HF, high fat; LF, low fat.
Table 2 Body composition of mice fed LF, HF and HF/FO diets either with or without adding a CB1-receptor antagonist
LF HF HF/FO
Control Rimonabant Control Rimonabant Control Rimonabant
Body mass (g) 29.09±0.62 26.05±0.63y 30.56±0.55 28.84±0.82 33.63±1.14w,z 29.19±1.38**
Lean carcass (g) 4.00±0.08 4.03±0.15 3.76±0.04* 3.73±0.06 4.21±0.18 z 3.89±0.13
Fat mass (g) 3.65±0.44 2.56±0.25 y 6.53±0.51* 4.86±0.51# 9.15±0.79w,z 6.09±0.88**
Muscular fat (g) 1.07±0.14 0.84±0.07 1.26±0.09 1.13±0.14 2.32±0.20w,z 1.40±0.24**
Visceral fat (g) 1.19±0.11 0.81±0.09 y 2.26±0.17* 1.77±0.14 2.84±0.25w 1.99±0.24**
Epididymal 0.69±0.05 0.51±0.04 y 1.49±0.10* 1.21±0.09# 1.81±0.21w 1.22±0.15**
Retroperitoneal 0.29±0.03 0.19±0.03 y 0.45±0.04* 0.28±0.03# 0.71±0.06w,z 0.46±0.07**
Mesenteric 0.20±0.05 0.12±0.04 0.32±0.04 0.29±0.05 0.32±0.09 0.31±0.08
Subcutaneous fat (g) 1.33±0.16 0.78±0.11y 2.89±0.26* 2.18±0.18 3.81±0.45w 2.50±0.39**
Abbreviations: FO, fish oil; HF, high fat; LF, low fat. Values are mean±s.e.m. for n¼7–8 mice; *, Po0.05 HF control versus LF control; w, Po0.05 HF/FO control
versus LF control; z, Po0.05 HF/FO control versus HF control; y, Po0.05 LF control versus LF rimonabant treatment; #, Po0.05 HF control versus HF rimonabant
treatment; **, Po0.05 HF/FO control versus HF/FO rimonabant treatment.
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group was significantly higher as compared with that in food
efficiency in the LF control group (113.7% higher in the
HF/FO control group compared with levels calculated in the
LF control group; P¼0.006) and the HF control group
(99.4% higher in the HF/FO control group compared with
levels calculated in the HF control group; P¼0.010).
Effects of dietary fat composition on lipid profile and lipogenic
markers in C57BL/6J mice
Plasma concentrations of triglycerides were significantly
lower in the HF/FO control group as compared with that in
the LF and HF control groups (Table 3). In the HF control
group as well as HF/FO control group, plasma cholesterol
concentrations were significantly elevated as compared with
that in the LF-fed control group. Hepatic triglycerides,
hepatic total cholesterol, free cholesterol and cholesterol
esters were significantly elevated in the HF group as
compared with that in the LF group (Table 3). The hepatic
levels of total cholesterol, free cholesterol and cholesterol
esters normalized in mice fed HF/FO as compared with that
in the HF group, and became indistinguishable from those in
LF controls. Hepatic triglyceride levels were decreased in the
HF/FO control group as compared with that in the HF
control group, but remained significantly elevated compared
with that in the LF control group. Both plasma leptin and
adiponectin levels were significantly increased in the HF/FO
control group as compared with that in the other control
groups (Table 3).
Consistent with previous data from our laboratory, hepatic
expression of genes encoding lipogenic enzymes (shown in
Figure 3) were significantly elevated in the HF control group
as compared with that in the LF control group, and in the
HF/FO group expression levels were similar to the LF control
group or even lower.
Effects of dietary fat composition on RQs and oxygen
consumption in C57BL/6J mice
As expected, calorimetry data showed higher RQs for mice in
the LF group as compared with those in the HF group and
the HF/FO group (Table 4). In the dark phase and in the light
phase, oxygen consumption and calculated energy expendi-
ture were significantly increased in HF-fed mice as compared
with that in the LF control group and the HF/FO control
group. There were no significant differences between the HF/
FO-fed and the LF-fed mice regarding oxygen consumption
or energy expenditure. There was a significant reduction in
Figure 2 (a) Fecal energy excretion. Residual energy in feces collected during 48 h, measured by bomb calorimetry. Open bars, control groups; black bars,
rimonabant treatment groups. Values are means±s.e.m. for n¼4–8 mice per group. HF C versus LF C, *P¼0.008; HF/FO C versus LF C, wP¼ 0.000; HF C versus HF/
FO C, zP¼ 0.037. (b) Energy absorption. Absorbed energy calculated from food intake in kilocalories per day minus residual fecal energy in kilocalories per day.
Open bars, control groups; black bars, rimonabant treatment groups. Values are means±s.e.m. for n¼4–8 mice per group. No significant differences. (c) Food
efficiency: Food efficiency over day 0–day 22 expressed in gram body weight gain per kilocalorie intake. Open bars, control groups; black bars, treatment groups.
Values are means±s.e.m. for n¼8 mice per group. *, HF/FO C versus LF C, P¼ 0.006; w, HF/FO C versus HF C, P¼0.010; z, LF R versus LF C, P¼0.002; y, HF R versus
HF C, P¼ 0.001; 8, HF/FO R versus HF/FO C, P¼0.000. Significant interaction between treatment and diet, P¼ 0.027. FO, fish oil; HF, high fat; HF C, high fat
control; LF, low fat; LF C, low fat control.
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CO2 production in HF/FO-fed mice as compared with that in
LF-fed and HF-fed mice.
Lipid oxidation was significantly increased in the HF
control group as compared with that in the LF control group
in the dark as well as light phase. Lipid oxidation was even
more pronounced in the HF/FO control group. HF/FO fed
mice had significantly elevated lipid oxidation compared
with that in HF-fed mice. In the light and in the dark phase,
Table 3 Hepatic and plasma parameters in mice fed LF, HF and HF/FO diets either with or without adding a CB1-receptor antagonist
LF HF HF/FO
Control Rimonabant Control Rimonabant Control Rimonabant
Plasma
Triglycerides (mmol l1) 0.92±0.14 0.68±0.10 1.07±0.12 1.03±0.17 0.70±0.06 0.48±0.10
Cholesterol (mmol l1) 3.59±0.18 3.09±0.21 5.93±0.26* 5.94±0.19 6.16±0.22w,z 6.14±0.36
Leptin (ngml1) 5.38±2.59 3.27±0.68 10.25±1.93 9.35±1.40 32.75±5.17w 11.68±3.44**
Resistin (ngml1) 3.43±0.55 3.03±0.16 5.87±0.59* 6.69±0.57 7.21±0.72w,z 4.13±0.75**
TNF-a (pgml1) 2.51±0.62 2.20±0.29 1.68±0.44 1.33±0.27 2.75±0.32 2.28±0.43
Adiponectin (mgml1) 10.72±0.97 12.36±2.42 9.03±0.35 10.04±0.53 23.07±2.29w 15.94±1.55**
Liver
Triglycerides (nmolmg1 liver) 17.29±1.30 14.61±0.67 40.79±0.88* 38.03±1.28 24.82±1.41w,z 26.32±1.99
Total cholesterol (nmolmg1 of liver) 4.88±0.27 5.24±0.35 7.23±0.21* 7.32±0.29 5.07±0.20z 5.72±0.14**
Free cholesterol (nmolmg1 of liver) 4.35±0.29 4.61±0.35 5.66±0.15* 5.47±0.26 4.41±0.14z 4.90±0.11**
Cholesterolesters (nmolmg1 of liver) 0.54±0.10 0.64±0.13 1.57±0.09* 1.86±0.12 0.66±0.09z 0.82±0.06
Phospholipids (nmolmg1 of liver) 24.98±1.10 24.40±0.66 24.48±0.34 25.39±0.23# 26.65±0.57 27.13±0.43
Abbreviations: FO, fish oil; HF, high fat; LF, low fat; TNF, tumor necrosis factor. Blood samples taken on the day the mice were killed. Values are mean±s.e.m. for
n¼6–8 mice; *, Po0.05 HF control versus LF control; w, Po0.05 HF/FO control versus LF control; z, Po0.05 HF/FO control versus HF control; y, Po0.05 LF control
versus LF rimonabant treatment; #, Po0.05 HF control versus HF rimonabant treatment; **, Po0.05 HF/FO control versus HF/FO rimonabant treatment.
Figure 3 Hepatic lipogenic gene expression. (a). Relative hepatic mRNA expression of Srebp-1c (srebf1) in control mice (white bars) and mice treated with
rimonabant (black bars) on either LF, HF or HF/FO. Results are normalized to b-actin. Values are means±s.e.m. for n¼3–8 mice per group. HF C versus LF C,
*P¼ 0.027; HF/FO C versus HF C, wP¼0.003. (b). Relative hepatic mRNA expression of Fasn in control mice (white bars) and mice treated with rimonabant (black
bars). Results are normalized to b-actin. Values are means±s.e.m. for n¼ 3–8 mice per group. HF C versus LF C, *P¼0.019; HF/FO C versus HF C, wP¼0.001. (c).
Relative hepatic mRNA expression of Acc1 (Acaca) in control mice (white bars) and mice treated with rimonabant (black bars). Results are normalized to b-actin.
Values are means±s.e.m. for n¼3–8 mice per group. HF C versus HF/FO C, *P¼ 0.012; HF/FO C versus LF C, wP¼0.034. (d). Relative hepatic mRNA expression of
Acc2 (Acacb) in control mice (white bars) and mice treated with rimonabant (black bars). Results are normalized to b-actin. Values are means±s.e.m. for n¼ 3–8 mice
per group. HF C versus HF/FO C, *P¼ 0.007; HF/FO C versus LF C, wP¼0.013. FO, fish oil; HF, high fat; HF C, high fat control; LF, low fat; LF C, low fat control.
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HF/FO-fed mice had significantly decreased carbohydrate
oxidation compared with both the HF control group and the
LF control group. In HF-fed mice carbohydrate oxidation was
also significantly decreased in the light phase and in the dark
phase as compared with that in the LF control group.
Effects of rimonabant treatment on body weight and body fat
mass in C57BL/6J mice on different diets
Treatment with rimonabant decreased body weight in all
three diet groups in the first week of treatment as compared
with the respective controls (Figure 1a). Approximately 1 week
after start of treatment, mice in the treatment groups gained
weight again. Yet, throughout the experiment, body weights
of mice in the treatment groups remained significantly lower
than that in the control groups. At day 22, on all three diets,
mice treated with rimonabant had gained significantly less
weight than non-treated mice (Figure 1b). The reduction
in body weight gain in treated mice appeared to be most
prominent in the HF/FO treatment group as compared with
that in the HF/FO control group. This was not caused by
diminished weight gain in the treated mice fed HF/FO
compared with treated mice fed LF or HF, but rather by a
higher weight gain in the untreated HF/FO group as compared
with that in the LF control group and the HF control group.
The effect of rimonabant treatment on body weight is
reflected by changes in adiposity (Table 2). This effect was most
prominent in mice fed the HF/FO diet. The reduction in fat
mass in all three treatment groups is due to reduction of both
abdominal fat mass and subcutaneous fat mass. Treatment with
rimonabant did not have any significant effect on lean mass of
mice in the three diet groups as compared with their controls.
Effects of rimonabant treatment on lipid profile and hepatic
lipogenic gene expression in C57BL/6J mice on different diets
Treatment with rimonabant did not affect plasma triglyce-
ride and plasma cholesterol (Table 3). Hepatic triglyceride
concentrations were also not affected by treatment with
rimonabant. In the HF/FO-fed mice treated with rimona-
bant, plasma levels of leptin and adiponectin were decreased
as compared with those in the respective controls. There was
a significant interaction between treatment and diet in
leptin levels (P¼0.002) as well as in adiponectin levels
(P¼0.013), meaning that post hoc analysis revealed no
treatment effect in LF-fed and in HF-fed mice, whereas
rimonabant treatment significantly reduced plasma levels of
leptin and adiponectin in HF/FO-fed mice.
Notably, we did not observe any decrease in hepatic
lipogenic gene expression in the rimonabant-treated groups
as compared with the respective control groups.
Effects of rimonabant treatment on food intake and ‘food
efficiency’ and fecal energy excretion in C57BL/6J mice on
different diets
We observed no effect of administering CB1-receptor
antagonist on food intake in the LF-fed treatment group
Table 4 Indirect calorimetry data from mice fed LF, HF and HF/FO diets either with or without adding a CB1-receptor antagonist
LF HF HF/FO
Control Rimonabant Control Rimonabant Control Rimonabant
O2 consumption(ml h
1)
Dark phase 22.73±0.76 22.08±0.72 26.51±0.54* 26.02±0.39 23.04±0.77z 24.36±0.27
Light phase 19.92±0.74 17.82±0.76 22.84±0.53* 22.08±0.39 19.71±0.53z 20.36±0.45
CO2 production (ml h
1)
Dark phase 22.39±0.86 20.29±0.65 21.70±0.41 20.95±0.26 17.72±0.62w,z 18.47±0.22
Light phase 18.32±0.95 15.22±0.66y 18.80±0.42 17.87±0.31 15.08±0.41w, z 15.47±0.34
RQ
Dark phase 0.98±0.01 0.92±0.01y 0.82±0.00* 0.81±0.00# 0.77±0.00w,z 0.76±0.00**
Light phase 0.92±0.02 0.85±0.01y 0.82±0.00* 0.81±0.00# 0.77±0.00w,z 0.76±0.00
EE per gram lean mass (kJ hg1)
Dark phase 0.48±0.02 0.46±0.01 0.54±0.01* 0.53±0.01 0.46±0.02z 0.49±0.01
Light phase 0.41±0.02 0.36±0.02 0.46±0.01* 0.45±0.01 0.39±0.01z 0.41±0.01
Lipid oxidation (mgh1)
Dark phase 1.3±1.1 10.4±0.9y 28.1±1.0* 29.4±0.7 35.2±0.8w,z 36.1±1.3
Light phase 9.2±1.9 15.8±0.8y 23.6±0.6* 24.4±0.6 30.8±0.9w,z 30.0±0.8
Carbohydrate oxidation (mgh1)
Dark phase 101.5±4.2 76.6±4.3y 46.4±1.7* 40.2±1.2# 26.4±1.3w,z 21.7±1.4**
Light phase 68.9±6.8 43.4±2.9y 41.5±1.0* 35.5±0.9# 21.4±1.5w,z 18.5±1.2
Abbreviations: EE, energy expenditure; FO, fish oil; HF, high fat; LF, low fat; RQ, respiratory quotient. Values are mean±s.e.m. for n¼7–8 mice; *, Po 0.05 HF
control versus LF control; w, Po0.05 HF/FO control versus LF control; z, Po0.05 HF/FO control versus HF control; y, Po0.05 LF control versus LF rimonabant
treatment; #, Po0.05 HF control versus HF rimonabant treatment; **, Po0.05 HF/FO control versus HF/FO rimonabant treatment.
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as compared with the LF-fed control group. However, after
start of treatment, food intake was significantly lower in
the HF treatment group and the HF/FO treatment group.
The effects on food intake diminished during the first week
of treatment. At day 4, there was no difference in food intake
between the HF treatment group and the HF control group
anymore, and after 10 days the difference in food intake had
also disappeared between the HF/FO treatment group and the
HF/FO control group (data not shown). The cumulative caloric
intake calculated for the treatment period was significantly
reduced in the HF/FO treatment group as compared with that
in the HF/FO control group (HF/FO treatment versus HF/FO
control Po0.001), and in the HF treatment group compared
with that in the HF control group (HF treatment versus HF
control, P¼0.02), as is illustrated in Figure 1c. However, there
were no significant differences in cumulative caloric intake
calculated from day 11 until day 22 (Figure 1d), illustrating the
observation that the effect of treatment with a CB1-receptor
antagonist on food intake is transient.
To assess if decreased absorption could contribute to
decreased weight gain in treated mice, we measured residual
energy contents in feces by bomb calorimetric analysis of
feces collected over a period of 48h. Treatment with CB1-
receptor antagonist had no significant effect on fecal energy
excretion on either diet (Figure 2a) and calculated as
absorbed energy (food intake in kcal 24h1 minus residual
fecal energy in kcal 24h1) the amount of absorbed energy
was not affected by treatment (Figure 2b).
On all three diets, rimonabant treatment led to significant
reduction in food efficiency (Figure 2c; LF treatment versus LF
control, P¼0.002; HF treatment versus HF control, P¼0.001;
HF/FO treatment versus HF/FO control, Po0.001). There was
a significant interaction between diet and treatment
(P¼0.027). Indeed, effect of treatment was most prominent
in the HF/FO treatment group as compared with that in the
HF/FO control group. Again, this was a consequence of higher
food efficiency in the HF/FO control group rather than of
lower food efficiency in the HF/FO treatment group.
Effects of rimonabant treatment on RQ and oxygen consumption
in C57BL/6J mice on different diets
Table 4 shows that treatment with rimonabant significantly
reduced the RQ during both the light phase and the dark
phase in LF-fed mice (light-phase LF treatment versus LF
control, P¼0.004, dark-phase LF treatment versus LF control
Po0.001) and in HF-fed mice (light-phase HF treatment
versus HF control, P¼0.003, dark-phase HF treatment versus
HF control, P¼0.033). In the HF/FO treatment group,
a significant reduction in RQ as compared with that in the
HF/FO control group was only observed in the dark phase
(HF/FO treatment versus HF/FO control, P¼0.011). A
significant increase in lipid oxidation and a significant
decrease in carbohydrate oxidation were observed in LF-fed
mice upon rimonabant treatment in the light phase as well
as in the dark phase. There was no treatment effect on lipid
oxidation in the HF groups or in the HF/FO groups. Yet, there
was a significant decrease in carbohydrate oxidation in the
HF treatment group as compared with that in the HF control
group in the light phase and in the dark phase, and in the
HF/FO treatment group compared with that in the HF/FO
control group only in the dark phase.
Rimonabant treatment did not affect oxygen consumption
or energy expenditure as calculated from indirect calorime-
try data, neither in the light phase nor in the dark phase, in
any of the groups (Table 4).
Discussion
In the present study, we compared the effects of treatment
with rimonabant, a selective endocannabinoid CB1-receptor
antagonist, on food intake and on hormonal and metabolic
characteristics, in young adult mice fed diets with differences
in the total amount and ratio of SFAs versus PUFAs. Despite
notable differences in hormonal and metabolic profiles
among mice fed the different experimental diets, we found
that rimonabant treatment prevented weight gain and
improved metabolic derangements, without major differ-
ences in energy intake and expenditure. This highlights a
role for the ECS in triglyceride deposition in adipose tissue as
well as in the liver irrespective of dietary fat content or
composition.
Compared with mice fed a fibered LF, carbohydrate-rich
diet, feeding a diet with HF content caused increase in body
fat mass and hyperleptinemia, and a massive increase in
hepatic triglyceride content in mice. These well-known
derangements are major risk factors for development
of hepatosteatitis and type-2 diabetes mellitus.30–32 The
increased hepatic fat depositionFbeing a hallmark of the
metabolic syndromeFappeared to be abolished when mice
were fed a diet with a fat content similar as the aforemen-
tioned HF diet, but in which 10% of the SFA were replaced by
PUFA derived from FO (HF/FO diet). We observed, however,
that lipid deposition inside adipose tissue as well as plasma
leptin levels were greatly augmented in HF/FO-fed mice as
compared with that in those fed the HF diet.
The finding that a 10% replacement of SFA by PUFA caused
reduction of hepatic triglyceride deposition almost back to
the level observed in the LF-fed mice fits well with the
documented effects of PUFA to stimulate hepatic lipid
utilization,33 and to reduce hepatic lipogenesis.24 Indeed,
mice in the present study fed the HF/FO diet showed reduced
hepatic gene expression levels of lipogenic enzymes Srebp-1c,
Acc1, Acc2 and Fasn compared with those observed in the HF
group. In addition, the rate of lipid oxidation assessed by
indirect calorimetry was clearly highest in the HF/FO group.
For these reasons, it is counterintuitive that ingestion of an
HF/FO-diet potentiated the level of body adiposity well
above the levels observed in the HF and LF group. Mice fed
the HF/FO diet showed significantly elevated plasma levels
of adiponectin, which could have, in part, prevented fat
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deposition in extra-adipose tissues, and at the same time,
mediated the increased expansion of adipose tissue in this
group. Such an effect has been proposed by Kim et al.34 who
showed that overexpression of adiponectin leading to
elevated plasma adiponectin levels, also led to increased
adipose tissue mass. Like in our study, the increased plasma
adiponectin levels together with expanded fat mass were
associated with normalization of hepatic and plasma lipid
profiles. Another issue relevant to the beneficial effect of the
HF/FO diet on metabolic endpoints while enhancing fat
mass (that is, relative to those observed in the HF diet
condition), is the observation that the HF/FO diet seems to
augment, percent-wise, the subcutaneous fat depot (sub-
cutaneous adipose tissue) more than the visceral fat depot
(visceral adipose tissue) as compared with the HF diet, and
with respect to the corresponding values at day 22 in the LF
diet. While both diets augment subcutaneous adipose tissue
more than visceral adipose tissue, the difference is approxi-
mately 20% higher with the HF/FO diet. In view of the well-
established strong connections between visceral adipose
tissue and some metabolic disorders,35 this perhaps may
have contributed to the higher adiponectin levels (despite
the stronger increase in body weight) and also the beneficial
effects on hepatic lipogenesis observed with the HF/FO diet.
The exaggerated expansion of adipose tissue of HF/FO-fed
mice as compared with the other groups could not be
attributed to an increase in food intake or to an increased
gastrointestinal absorption rate, which indicates that these
animals were more ‘food efficient’ than those fed the HF and
LF diet. Indeed, calculation of body weight gain per absorbed
energy content revealed a doubling of food efficiency in the
HF/FO group as compared with that in the HF and LF groups.
Food efficiency depends on energy expenditure (EE), which
in turn is comprised of resting metabolic rate, activity
thermogenesis, and thermic effects of food. Resting meta-
bolic rate comprises thermogenesis, detoxification, main-
tenance of membrane potentials and tissue differentiation
and tissue maintenance. EE during the light and the dark
phase and resting metabolic rate calculated from indirect
calorimetry were indeed lower in the HF/FO group as
compared with that in the HF group, which may have
underlied the increased food efficiency and adipose tissue
expansion in the HF/FO group relative to the HF group.
Compared with LF-fed mice, however, this lowering of EE
and resting metabolic rate in the HF/FO group was not
significant. This discrepancy of increased food efficiency and
weight gain in the HF/FO group versus the LF group without
alterations in EE may be explained by a shift between the
various components of energy expenditure without affecting
total energy expenditure. For example, a decrease in the
thermic effects of food could make more energy available for
storage and tissue expansion. We are currently performing
experiments to specifically address these possibilities.
As pointed out above, rimonabant treatment prevented
weight gain and ameliorated adiposity in all three experi-
mental diet groups despite marked differences in adiposity
and metabolic profiles between the groups. After start of
treatment with the CB1-receptor antagonist, there was a
slight and temporal reduction of food intake in the HF and
HF/FO group, which explains the reduction in body weight
by rimonabant-treatment only to a limited degree. Since
total absorbed energy (as assessed by bomb calorimetry of
feces) was not different among groups, this indicates that
body weight loss induced by treatment with rimonabant was
mediated by changes in metabolism. In fact, rimonabant
treatment rendered mice remarkably food inefficient, such
that the diet-induced differences in food efficiency were
entirely lost upon rimonabant treatment. However, the
effects of rimonabant could not be explained by differences
in metabolic rate since EE measured by indirect calorimetry
was similar in treated versus non-treated mice in the
respective diet groups. It is tempting to speculate that
metabolic coupling was affected by rimonabant treatment
in the different diet groups, which contributed to prevent
weight gain. While efficiency of metabolic coupling as
a potential mechanism has to be addressed, our results
regarding discrepancies between weight loss by blockade of
CB1 signaling, without changes in energy intake and
expenditure corresponds with findings in several other
recent studies.10,36 Reports that, in contrast to these results,
do demonstrate an increase in EE in animals and humans
treated with a CB1-receptor antagonist
20,37–39 frequently
employ an acute rather than continuous treatment. Kunz
et al.37 clearly demonstrated rapid development of tolerance
to rimonabant towards induction of oxygen consumption,
stressing differences in effects of acute versus chronic
treatment. Moreover, investigators frequently normalize EE
and oxygen consumption to total body weight, thereby
ignoring fat-free versus fat mass, which causes an over-
estimation of EE when fat mass is lost without changes in
lean mass.20,38
The effect of CB1-receptor antagonism to prevent weight
gain and to ameliorate adiposity levels in the LF, HF as well as
HF/FO-fed mice corresponds with other studies showing
treatment effects irrespective of diet composition.14–16,18,21 It
is, however, rather surprising in light of the findings by others
showing that HF diets given to mice cause dysregulation of
the ECS, either via alterations in the expression of CB1
receptors, via alterations in the levels of endogenous ligands,
or both.17,40–42 Also the fatty acid composition of dietary fat
may influence endocannabinoid action.43 For example, the
presence or absence of n-3 PUFAs in the diet affects
endocannabinoid levels in the brain, as shown by Berger
et al.44 and Watanabe et al.45 Batetta et al.46 recently found
that dietary n-3 PUFAs can reduce inflammatory markers and
liver triglyceride levels, and these effects were associated
with lower levels of endocannabinoid ligands in peripheral
organs. Finally, there is an in vitro study showing that n-3
PUFA can reduce the levels of both anandamide and 2-AG in
differentiated mouse adipocytes, whereas n-6 PUFAs (that is,
arachidonic acid) were found to increase endocannabinoid
levels.47 The efficacy of an antagonist such as rimonabant
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should depend on the extent of tonic activation of CB1
receptors by, among other things, endocannabinoids. Since
n-6 PUFA content is relatively high in FO (that is, with a ratio
of n-6/n-3 of 0.4 in the HF/FO diet, and no n-6 at all in the
HF diet), this may provide an explanation for the finding
that rimonabant is more efficacious in mice fed the HF/FO
diet to induce weight loss in the present study.
Associated with a reversal of HF-diet-induced obesity by
rimonabant, studies generally reported lowering of hepatic
triglyceride accumulation and plasma leptin levels, and
increased plasma adiponectin levels by rimonabant treat-
ment.11,15,18,21 The reversal of these comorbidities by
rimonabant was not observed in the present study. It is
possible that the discrepancy between the results of our
study and others is due to differences in the age of mice and
experimental duration. In our study, endpoint measure-
ments were performed at 14 weeks of age, whereas in all
other studies mice used were 6 months or older, and mice
in those studies were subjected to experimental diets for
months.11,15,18,21 Nevertheless, we did find profound inhi-
bitory effects of the HF/FO diet on markers for hepatic
lipogenesis relative to the HF diet condition. It was
previously suggested by Osei-Hyiaman et al.11 that HF-diet-
induced obesity was a consequence of increased lipogenesis
(by increased hepatic Srebp-1c expression), with a permissive
role for hepatic CB1 signaling in these effects. This is in
contrast with our results that showed reduction of body
weight gain in mice treated with rimonabant on all three
diets, and, in fact, reduction of body weight gain was most
pronounced in treated mice on the HF/FO diet in which
lipogenesis in liver was suppressed. Thus, our results suggest
that suppression of hepatic lipogenesis does not play a role
in the effect of rimonabant on body weight, at least in young
adult mice. This fits with the most recent observation
of Osei-Hyiaman et al.20 that liver-specific CB1
/ mice are
not resistant to diet-induced obesity, whereas total CB1
/
mice are.
In conclusion, our results show that treatment with a CB1-
receptor antagonist is not only effective in reducing body
weight gain in mice fed an HF diet based on SFAs, but that a
significant reduction in body weight is achieved irrespective
of dietary fat quality and quantity. Furthermore, the effect of
chronic rimonabant treatment to limit body weight gain
occurs independent of basic lipogenic activity and, in fact,
appears to be most pronounced in mice fed a diet with a
mixed SFA/PUFA composition, by which lipogenic activity
was lowest. Finally, we demonstrated that SFA replacement
in an HF diet by PUFAs not only results in improvement of
HF-diet-induced metabolic derangements, but also in aug-
mentation of adipose tissue stores. While the effects of
dietary PUFA replacement in an HF diet on expansion of
adipose tissue might allow the favorable effects of dietary
PUFAs on dyslipidemia and hepatic steatosis, this might be a
risky trade-off in light of other disadvantageous effects of
weight gain. Thus, if FO supplements are used to prevent the
adverse metabolic effects of a Western-type diet in children
and adolescents, based on the findings in the present study,
the outcome will be an exacerbation of the development of
obesity in young people. If other preventive measures (for
example, exercise programs, avoiding Western-type diets,
and so on) turn out to be fruitless, improvement of
pharmacotherapy might remain the last resort for the
treatment of obesity at exceedingly young age.
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements
We thank Solvay for providing rimonabant. This study was
financially supported by a grant from Kruidvat and UMCG to
the Groningen Expert Centre on Childhood Obesity (to PJJS)
and from the Dutch Diabetes Foundation (to GvD). We
thank Mark Doornbos for technical assistance.
References
1 Di Marzo V, Matias I. Endocannabinoid control of food intake
and energy balance. Nat Neurosci 2005; 8: 585–589.
2 Bellocchio L, Cervino C, Pasquali R, Pagotto U. The endocanna-
binoid system and energy metabolism. J Neuroendocrinol 2008; 20:
850–857.
3 Matias I, Di Marzo V. Endocannabinoids and the control of
energy balance. Trends Endocrinol Metab 2007; 18: 27–37.
4 Williams CM, Kirkham TC. Anandamide induces overeating:
mediation by central cannabinoid (CB1) receptors. Psycho-
pharmacology (Berl) 1999; 143: 315–317.
5 Hao S, Avraham Y, Mechoulam R, Berry EM. Low dose
anandamide affects food intake, cognitive function, neuro-
transmitter and corticosterone levels in diet-restricted mice.
Eur J Pharmacol 2000; 392: 147–156.
6 Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid
levels in rat limbic forebrain and hypothalamus in relation
to fasting, feeding and satiation: stimulation of eating by
2-arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550–557.
7 Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z et al.
Leptin-regulated endocannabinoids are involved in maintaining
food intake. Nature 2001; 410: 822–825.
8 Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner
TI. Increased mortality, hypoactivity, and hypoalgesia in canna-
binoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 1999;
96: 5780–5785.
9 Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1
cannabinoid receptor knockout in mice leads to leanness,
resistance to diet-induced obesity and enhanced leptin sensiti-
vity. Int J Obes Relat Metab Disord 2004; 28: 640–648.
10 Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C,
Schubert M et al. The endogenous cannabinoid system affects
energy balance via central orexigenic drive and peripheral
lipogenesis. J Clin Invest 2003; 112: 423–431.
11 Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S
et al. Endocannabinoid activation at hepatic CB1 receptors
stimulates fatty acid synthesis and contributes to diet-induced
obesity. J Clin Invest 2005; 115: 1298–1305.
12 Despres JP, Golay A, Sjostrom L. Effects of rimonabant on
metabolic risk factors in overweight patients with dyslipidemia.
N Engl J Med 2005; 353: 2121–2134.
Endocannabinoid signaling, dietary fat and obesity
AH Koolman et al
383
International Journal of Obesity
13 Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects
of the cannabinoid-1 receptor blocker rimonabant on weight
reduction and cardiovascular risk factors in overweight patients:
1-year experience from the RIO-Europe study. Lancet 2005; 365:
1389–1397.
14 Hildebrandt AL, Kelly-Sullivan DM, Black SC. Antiobesity effects
of chronic cannabinoid CB1 receptor antagonist treatment in
diet-induced obese mice. Eur J Pharmacol 2003; 462: 125–132.
15 Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P,
Maffrand JP et al. Anti-obesity effect of SR141716, a CB1 receptor
antagonist, in diet-induced obese mice. Am J Physiol Regul Integr
Comp Physiol 2003; 284: R345–R353.
16 Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL.
Appetite suppression and weight loss after the cannabinoid
antagonist SR 141716. Life Sci 1998; 63: L113–L117.
17 Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L,
Cervino C et al. Regulation, function, and dysregulation of
endocannabinoids in models of adipose and beta-pancreatic cells
and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006;
91: 3171–3180.
18 Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux
A et al. The CB1 receptor antagonist rimonabant reverses the diet-
induced obesity phenotype through the regulation of lipolysis
and energy balance. FASEB J 2005; 19: 1567–1569.
19 Herling AW, Kilp S, Elvert R, Haschke G, Kramer W. Increased
energy expenditure contributes more to the body weight-
reducing effect of rimonabant than reduced food intake in
candy-fed Wistar rats. Endocrinology 2008; 149: 2557–2566.
20 Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J,
Jeong WI et al. Hepatic CB1 receptor is required for development
of diet-induced steatosis, dyslipidemia, and insulin and leptin
resistance in mice. J Clin Invest 2008; 118: 3160–3169.
21 Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B,
O’Connor SE et al. The anti-obesity effect of rimonabant is
associated with an improved serum lipid profile. Diabetes Obes
Metab 2005; 7: 65–72.
22 Pellizzon M, Buison A, Ordiz Jr F, Santa AL, Jen KL. Effects of
dietary fatty acids and exercise on body-weight regulation and
metabolism in rats. Obes Res 2002; 10: 947–955.
23 Lin J, Yang R, Tarr PT, Wu PH, Handschin C, Li S et al.
Hyperlipidemic effects of dietary saturated fats mediated through
PGC-1beta coactivation of SREBP. Cell 2005; 120: 261–273.
24 Benhizia F, Hainault I, Serougne C, Lagrange D, Hajduch E, Guichard
C et al. Effects of a fish oil-lard diet on rat plasma lipoproteins, liver
FAS, and lipolytic enzymes. Am J Physiol 1994; 267: E975–E982.
25 Dentin R, Benhamed F, Pegorier JP, Foufelle F, Viollet B, Vaulont S
et al. Polyunsaturated fatty acids suppress glycolytic and
lipogenic genes through the inhibition of ChREBP nuclear
protein translocation. J Clin Invest 2005; 115: 2843–2854.
26 Jequier E, Acheson K, Schutz Y. Assessment of energy expenditure
and fuel utilization in man. Annu Rev Nutr 1987; 7: 187–208.
27 Lusk G. The Elements of the Science of Nutrition. 4th edn. Johnson
Reprint Corp.: New York, 1924.
28 Bligh EG, Dyer WJ. A rapid method of total lipid extraction and
purification. Can J Biochem Physiol 1959; 37: 911–917.
29 Bo¨ttcher CFJ, van Gent CM, Pries C. A rapid and sensitive
sub-micro phosphorus determination. Anal Chim Acta 1961; 24:
203–204.
30 den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic
steatosis: a mediator of the metabolic syndrome. Lessons from
animal models. Arterioscler Thromb Vasc Biol 2004; 24: 644–649.
31 Haffner SM. The prediabetic problem: development of non-
insulin-dependent diabetes mellitus and related abnormalities.
J Diabetes Complications 1997; 11: 69–76.
32 Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-
Jarvinen H. Increased liver fat, impaired insulin clearance, and
hepatic and adipose tissue insulin resistance in type 2 diabetes.
Gastroenterology 2008; 135: 122–130.
33 Clarke SD. Polyunsaturated fatty acid regulation of gene
transcription: a molecular mechanism to improve the metabolic
syndrome. J Nutr 2001; 131: 1129–1132.
34 Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME,
Hofmann SM et al. Obesity-associated improvements in meta-
bolic profile through expansion of adipose tissue. J Clin Invest
2007; 117: 2621–2637.
35 Lebovitz HE. The relationship of obesity to the metabolic
syndrome. Int J Clin Pract Suppl 2003; 134: 18–27.
36 Woolcott OO, Stefanovski D, Harrison LN, Mooradian V,
Zheng D, Lottati M et al. Rimonabant reduces body weight
and adiposity independent of changes in resting metabolic
rate and food intake. Diabetologia 2008; 51 (Suppl 1): S316
(abstract).
37 Kunz I, Meier MK, Bourson A, Fisseha M, Schilling W. Effects of
rimonabant, a cannabinoid CB1 receptor ligand, on energy
expenditure in lean rats. Int J Obes (Lond) 2008; 32: 863–870.
38 Herling AW, Gossel M, Haschke G, Stengelin S, Kuhlmann J,
Muller G et al. CB1 receptor antagonist AVE1625 affects
primarily metabolic parameters independently of reduced food
intake in Wistar rats. Am J Physiol Endocrinol Metab 2007; 293:
E826–E832.
39 Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ
et al. The acyclic CB1R inverse agonist taranabant mediates
weight loss by increasing energy expenditure and decreasing
caloric intake. Cell Metab 2008; 7: 68–78.
40 Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA
et al. Endocannabinoid dysregulation in the pancreas and adipose
tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 2008;
16: 553–565.
41 D’Eon TM, Pierce KA, Roix JJ, Tyler A, Chen H, Teixeira SR. The
role of adipocyte insulin resistance in the pathogenesis of
obesity-related elevations in endocannabinoids. Diabetes 2008;
57: 1262–1268.
42 Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G
et al. The endogenous cannabinoid system stimulates glucose
uptake in human fat cells via phosphatidylinositol 3-kinase and
calcium-dependent mechanisms. J Clin Endocrinol Metab 2007;
92: 4810–4819.
43 Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, Di Marzo V.
Dysregulation of peripheral endocannabinoid levels in hypergly-
cemia and obesity: effect of high fat diets. Mol Cell Endocrinol
2008; 286: S66–S78.
44 Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V.
Anandamide and diet: inclusion of dietary arachidonate and
docosahexaenoate leads to increased brain levels of the corres-
ponding N-acylethanolamines in piglets. Proc Natl Acad Sci USA
2001; 98: 6402–6406.
45 Watanabe S, Doshi M, Hamazaki T. n-3 Polyunsaturated fatty acid
(PUFA) deficiency elevates and n-3 PUFA enrichment reduces
brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot
Essent Fatty Acids 2003; 69: 51–59.
46 Batetta B, Griinari M, Carta G, Murru E, Ligestri A, Cordeddu L
et al. Endocannabinoids may mediate the ability of (n-3) fatty
acids to reduce ectopic fat and inflammatory mediators in obese
Zucker rats. J Nutr 2009; 139: 1495–1501.
47 Matias I, Carta G, Murru E, Petrosino S, Banni S, Di Marzo V.
Effect of polyunsaturated fatty acids on endocannabinoid and
N-acyl-ethanolamine levels in mouse adipocytes. Biochim Biophys
Acta 2008; 1781: 52–60.
Endocannabinoid signaling, dietary fat and obesity
AH Koolman et al
384
International Journal of Obesity
